건선 바이오시밀러 시장 예측(-2030년) : 제품 유형, 치료 유형, 용도, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Psoriasis Biosimilars Market is accounted for $10.27 billion in 2024 and is expected to reach $25.31 billion by 2030 growing at a CAGR of 12.2% during the forecast period. Psoriasis biosimilars are biologic drugs designed to treat psoriasis, a chronic autoimmune skin condition, by mimicking the action of reference biologics (original biologic drugs). These biosimilars are developed to have similar safety, efficacy, and quality to the reference product but are typically offered at a lower cost. They are used to reduce inflammation, control skin cell turnover, and manage symptoms in patients with moderate to severe plaque psoriasis. Psoriasis biosimilars undergo rigorous clinical testing to ensure they match the reference product's therapeutic effects.

According to the National Psoriasis Foundation, more than 8 million Americans have psoriasis.

Market Dynamics:

Driver:

Increasing prevalence of psoriasis

As the number of individuals diagnosed with psoriasis rises globally, there is a growing demand for effective, affordable treatments. Biosimilars offer a cost-efficient alternative to expensive reference biologics, making them an attractive option for healthcare systems facing rising treatment costs. The increasing incidence of moderate to severe psoriasis, particularly in regions with large populations, creates a substantial market opportunity for biosimilars. Additionally, greater awareness and earlier diagnosis of the condition further contribute to the demand for psoriasis biosimilars, boosting market expansion.

Restraint:

Physician and patient resistance

Physician and patient resistance to psoriasis biosimilars primarily stems from concerns about their efficacy, safety, and potential differences from reference biologics. Physicians may hesitate to prescribe biosimilars due to limited long-term clinical data or uncertainty regarding their interchangeability with original biologics. Patients often fear that biosimilars may not offer the same level of effectiveness or might cause adverse effects. This skepticism hampers market growth by slowing the adoption of biosimilars, despite their cost advantages.

Opportunity:

Expanded access to healthcare services in emerging markets

Since healthcare infrastructure improves in emerging regions, more patients gain access to advanced treatments for chronic conditions like psoriasis. Biosimilars, being cost-effective alternatives to expensive reference biologics, offer an affordable treatment option, particularly in price-sensitive markets. The increasing adoption of biosimilars is further supported by growing awareness among healthcare professionals and patients, as well as the regulatory push for biosimilar approvals. This broader access helps meet the rising demand for psoriasis treatments, contributing to market expansion in emerging economies.

Threat:

High development and manufacturing costs

High development and manufacturing costs in psoriasis biosimilars arise from the complex processes involved in creating biologic drugs, such as cell-line development, protein production, and extensive clinical testing to ensure safety and efficacy. Additionally, stringent regulatory requirements further increase costs. These high expenses can limit the affordability of biosimilars, hindering their widespread adoption, especially in price-sensitive markets.

Covid-19 Impact

The covid-19 pandemic impacted the psoriasis biosimilars market by disrupting supply chains, delaying clinical trials, and limiting healthcare access due to lockdowns. This led to a temporary slowdown in biosimilar adoption. However, the growing demand for affordable treatments, along with increased focus on cost-effective healthcare solutions, accelerated the market post-pandemic. Additionally, the rise in telemedicine helped maintain treatment continuity, boosting interest in biosimilars as an accessible, lower-cost alternative to original biologics for psoriasis management.

The biologic therapy segment is expected to be the largest during the forecast period

The biologic therapy segment is predicted to secure the largest market share throughout the forecast period. Biosimilars are designed to replicate the efficacy, safety, and quality of reference biologics at a lower cost. These treatments help control inflammation, reduce skin cell turnover, and alleviate symptoms in patients with moderate to severe psoriasis. The use of biosimilars in biologic therapy provides a more affordable and accessible option for patients, expanding treatment opportunities.

The plaque psoriasis segment is expected to have the highest CAGR during the forecast period

The plaque psoriasis segment is anticipated to witness the highest CAGR during the forecast period. Psoriasis biosimilars in plaque psoriasis applications are designed to provide effective, cost-efficient alternatives to reference biologics for managing moderate to severe plaque psoriasis. The use of biosimilars offers a more affordable treatment option while maintaining similar safety and efficacy profiles as original biologics. As plaque psoriasis is one of the most common forms, the demand for biosimilars in its treatment continues to grow, enhancing patient accessibility to effective therapies.

Region with largest share:

Asia Pacific is expected to register the largest market share during the forecast period driven by the increasing prevalence of psoriasis, rising healthcare costs, and growing access to advanced treatments. Key players in the market include Dr. Reddy's Laboratories, Samsung Bioepis, Biocon, and Mylan. The growing adoption of biosimilars combined with supportive regulatory frameworks and improving healthcare infrastructure, is propelling market growth. As awareness and healthcare access improve, the Asia-Pacific psoriasis biosimilars market is expected to continue its robust growth trajectory.

Region with highest CAGR:

North America is expected to witness the highest CAGR over the forecast period fuelled by the growing demand for affordable biologic treatments. The region is home for key players such as Amgen, Sandoz, Pfizer, and Celltrion Healthcare. The region also has strong regulatory support from the FDA. With the increasing acceptance of biosimilars among healthcare providers and patients, the North American psoriasis biosimilars market is poised for continued expansion.

Key players in the market

Some of the key players profiled in the Psoriasis Biosimilars Market include Amgen, Pfizer, Mylan, Eli Lilly, Boehringer Ingelheim, Coherus BioSciences, AbbVie, Novartis, Teva Pharmaceuticals, Glenmark Pharmaceuticals, Zydus Cadila, Lupin, Biocon Biologics, Alvotech, Hetero, Cipla, Hisun Biopharma and BIOCAD.

Key Developments:

In December 2024, Biocon Biologics has received the USFDA nod to launch the biosimilar version of Janssen's Stelara (Ustekinumab) used for the treatment of autoimmune disorders such as Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. The biosimilar will be marketed under brand name Yesintek.

In April 2024, Alvotech and Teva Pharmaceuticals received Food and Drug Administration (FDA) approval for Selarsdi, a biosimilar of Johnson & Johnson's Stelara, a leading treatment for moderate to severe psoriasis and other autoimmune conditions. This approval marks a significant milestone in the competitive landscape for psoriasis treatment, as Stelara has been a top-selling biologic with billions in annual sales.

Products Covered:

• Tumor Necrosis Factor (TNF) Inhibitors
• Interleukin Inhibitors
• Rituximab Biosimilars
• Etanercept Biosimilars
• Other Products

Therapy Types Covered:

• Topical Therapy
• Systemic Therapy
• Biologic Therapy
• Other Therapy Types

Applications Covered:

• Plaque Psoriasis
• Guttate Psoriasis
• Inverse Psoriasis
• Pustular Psoriasis
• Erythrodermic Psoriasis
• Other Applications

End Users Covered:

• Hospitals
• Clinics
• Homecare Settings
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Psoriasis Biosimilars Market, By Product

• 5.1 Introduction
• 5.2 Tumor Necrosis Factor (TNF) Inhibitors
  • 5.2.1 Adalimumab Biosimilars
  • 5.2.2 Infliximab Biosimilars
• 5.3 Interleukin Inhibitors
  • 5.3.1 IL-17 Inhibitors
  • 5.3.2 IL-12/23 Inhibitors
  • 5.3.3 IL-23 Inhibitors
• 5.4 Rituximab Biosimilars
• 5.5 Etanercept Biosimilars
• 5.6 Other Products

6 Global Psoriasis Biosimilars Market, By Therapy Type

• 6.1 Introduction
• 6.2 Topical Therapy
• 6.3 Systemic Therapy
• 6.4 Biologic Therapy
• 6.5 Other Therapy Types

7 Global Psoriasis Biosimilars Market, By Application

• 7.1 Introduction
• 7.2 Plaque Psoriasis
• 7.3 Guttate Psoriasis
• 7.4 Inverse Psoriasis
• 7.5 Pustular Psoriasis
• 7.6 Erythrodermic Psoriasis
• 7.7 Other Applications

8 Global Psoriasis Biosimilars Market, By End User

• 8.1 Introduction
• 8.2 Hospitals
• 8.3 Clinics
• 8.4 Homecare Settings
• 8.5 Other End Users

9 Global Psoriasis Biosimilars Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Amgen
• 11.2 Pfizer
• 11.3 Mylan
• 11.4 Eli Lilly
• 11.5 Boehringer Ingelheim
• 11.6 Coherus BioSciences
• 11.7 AbbVie
• 11.8 Novartis
• 11.9 Teva Pharmaceuticals
• 11.10 Glenmark Pharmaceuticals
• 11.11 Zydus Cadila
• 11.12 Lupin
• 11.13 Biocon Biologics
• 11.14 Alvotech
• 11.15 Hetero
• 11.16 Cipla
• 11.17 Hisun Biopharma
• 11.18 BIOCAD